Tianjin Pharmaceutical Da Ren Tang (SHA:600329) obtained drug registration from China's medical products administrator for saxagliptin and metformin hydrochloride sustained-release tablets.
The combination therapy is used for treating type two diabetes, according to a Friday filing with the Shanghai bourse.
Shares of the pharmaceutical company rose 1% in recent trade.